Sharon Kell, Author at Kidney Cancer Support Network

Lenvatinib plus everolimus improves progression-free survival in renal cell carcinoma

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week show that lenvatinib (Lenvima) plus everolimus (Afinitor) in kidney cancer significantly improved progression free survival (PFS) compared with everolimus or lenvatinib alone. Patients with metastatic renal cell carcinoma (mRCC) treated with lenvatinib plus everolimus following one prior VEGF targeted therapy […]

Jun 14, 2016 / Comments Off / Sharon Kell

HIF-2α inhibitor shows promise in renal cell carcinoma

The results of a first-in-human phase I clinical trial with a new drug called PT2385 were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago last week. PT2385 is an inhibitor of hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney and other […]

Jun 14, 2016 / Comments Off / Sharon Kell

Effectiveness of nivolumab persists long-term in advanced renal cell carcinoma

Follow-up data from phase I and phase II clinical trials with nivolumab were presented at the American Society of Clinical Oncology (ASCO) in Chicago last week, showing that about one-third of patients with advanced renal cell carcinoma (RCC) survival for 4 or 5 years or more following treatment with nivolumab (Opdivo) in the second-line. These […]

Jun 14, 2016 / Comments Off / Sharon Kell

Cabozantinib extends survival in advanced kidney cancer compared to axitinib

Results from the phase III METEOR clinical trial, which compares cabozantinib (Cabometxy) with everolimus (Afinitor) in patients with advanced renal cell carcinoma (RCC) who have had prior anti-angiogenic therapy, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week. The results showed almost a 30% increase in overall survival (OS) compared […]

Jun 14, 2016 / Comments Off / Sharon Kell

Nivolumab extends survival for advanced renal cell carcinoma patients treated beyond disease progression

Results from the phase III CheckMate-025 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago last week, showed the immunotherapy drug nivolumab, a checkpoint inhibitor, to be a safe and effective therapy for kidney cancer, even in patients who continued treatment after their disease progressed. Traditionally, kidney cancer drugs are […]

Jun 13, 2016 / Comments Off / Sharon Kell

Pazopanib before surgery is safe for metastatic kidney cancer

A recent study reported in the journal JAMA Oncology and conducted by Professor Thomas Powles and his team from Barts Cancer Institute, Queen Mary University of London, showed that the majority of patients with clear cell renal cell cancer (RCC) saw benefit from pazopanib therapy before undergoing cytoreductive nephrectomy. There were 104 patients with previously untreated metastatic clear […]